Global Expansion StageBio operates eight U.S. facilities and one in Germany, serving a broad international customer base across the Americas, Europe, Australia, and Asia. This global footprint offers opportunities to expand service offerings to new geographical markets and strengthen relationships with internationally-based biotech and pharmaceutical companies.

Innovative Partnerships Recent collaborations with companies like Pathcore and Insolcorp highlight StageBio's focus on digital pathology solutions and advanced specimen management. Leveraging these partnerships can present cross-selling opportunities for complementary technology products and services within the research ecosystem.

Leadership & Growth With recent leadership changes including new CEOs and a Head of Commercial appointed in 2024, StageBio shows a strategic focus on organizational growth and market expansion, making it a promising partner for customized research services tailored to evolving client needs.

Service Diversification StageBio's comprehensive offerings, from GLP-compliant histology to immunohistochemistry and neuropathology, enable sales teams to target a wide range of biotech and pharma clients requiring integrated preclinical and clinical research solutions.

Investment & Innovation Ongoing investments in facility upgrades and technology infrastructure demonstrate StageBio’s commitment to quality and innovation, providing opportunities to promote advanced research capabilities and digital services to prospective clients seeking cutting-edge histopathology solutions.